Monoclonal Antibodies Market Size to Reach USD 558.26 Billion in 2032
The Monoclonal Antibodies Market size was USD 232.58 billion in 2024 and is expected to register a revenue CAGR of 11.5% during the forecast period
20th May, 2025 – Increasing applications of mAb therapies for targeted therapies is a key driver driving monoclonal antibodies market revenue growth. The development of immunotherapy has considerably improved the prognosis and life expectancy of people suffering from numerous diseases, particularly cancer. Immunotherapeutic techniques include cancer vaccines, oncolytic viruses, adoptive transfer of ex vivo activated T and natural killer cells, and administration of recombinant proteins and, especially, mAbs that either co-stimulate cells or block checkpoint mechanisms.
On October 2024, Alvotech and Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd., announced that the FDA has approved SELARSDI (ustekinumab-aekn) in a novel formulation, 130 mg/26 mL (5 mg/mL) solution in a single-dose vial for intravenous infusion. Ustekinumab is a human monoclonal antibody that exclusively targets the p40 protein, which is found in both interleukin (IL)-12 and IL-23 cytokines and plays an important role in the treatment of immune-mediated disorders such as psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn’s disease.
Fluid and cold chain management are key issues in monoclonal antibody production, affecting the overall efficiency and quality of the process. Maintaining regular fluid flow rates, preventing air entrapment and contamination, and ensuring antibodies transfer smoothly and safely are all crucial. To properly overcome these fluid management challenges, sophisticated technology and precise process control must be implemented.
Key Highlights:
- Fully human segment is expected to register the largest market share over the forecast period. Fully human monoclonal antibodies are obtained exclusively from human sources, which reduces immunological rejection and improves therapeutic outcomes. This strategy addresses the ethical and safety considerations that come with older procedures. Humanized development techniques have improved dramatically over the last two decades, becoming crucial to the biotechnology industry.
- Oncology segment is expected to account for the largest growth rate over the forecast period. According to the American Cancer Society, in 2025, the estimated number of new cases of Hodgkin lymphoma in the United States is 8,720 (4,840 males and 3,880 females), with 1,150 fatalities (720 males and 430 females). Hodgkin lymphoma can affect both children and adults, however it is more frequent in early adulthood (particularly in the 20s). The risk of Hodgkin lymphoma increases again in late adulthood (beyond the age of 55). Overall, the average age at diagnosis is 39.
- North America accounted for the largest market revenue share in the monoclonal antibodies market in 2024 due to the rising prevalence of chronic and autoimmune diseases and Increased investment in biologics R&D. On November 2024, UCB, a global biopharmaceutical firm, said today that the FDA has approved BIMZELX (bimekizumab-bkzx) for the treatment of individuals with moderate-to-severe hidradenitis suppurativa (HS). BIMZELX is the first and only approved drug that selectively inhibits both interleukin 17F (IL-17F) and interleukin 17A.
- Some major companies in the market report include Bristol-Myers Squibb, F. Hoffman-La Roche Ltd., Novartis AG, Merck KGaA, Pfizer Inc, GlaxoSmithKline plc, AstraZeneca plc, Eli Lilly and Company, Johnson and Johnson, Viatris Inc., Sanofi, Bayer AG, Daiichi Sankyo Company, Limited, Amgen Inc., and Biogen.
- On February 2025, Harbour BioMed, a global biopharmaceutical company dedicated to developing innovative antibody therapies in immunology and oncology, has entered a strategic partnership with Insilico Medicine, a clinical-stage biotechnology firm specializing in generative AI. The collaboration aims to accelerate the discovery and development of novel therapeutic antibodies by combining Harbour BioMed’s expertise in antibody discovery with Insilico Medicine’s advanced AI technology.
- On March 2024, Roche Pharma India has launched Vabysmo (faricimab) to treat neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME). Vabysmo is the first dual-pathway inhibitor, targeting and inhibiting two disease processes associated with vision-threatening retinal diseases.
Unlock the key to transforming your business strategy with our Monoclonal Antibodies Market size insights:
Navistrat Analytics has segmented monoclonal antibodies market size based on source, production type, application, and end-use:
- Source Outlook (Revenue, USD Billion; 2022-2032)
- Murine
- Chimeric
- Humanized
- Fully Human
- Production Type Outlook (Revenue, USD Billion; 2022-2032)
- In Vitro
- Ex Vivo
- Application Outlook (Revenue, USD Billion; 2022-2032)
- Oncology
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Leukemia
- Lymphoma
- Others
- Autoimmune Diseases
- Rheumatoid Arthritis
- Psoriasis
- Crohn’s Disease
- Multiple Sclerosis
- Others
- Infectious Diseases
- Cardiovascular Diseases
- Neurological Diseases
- Hematological Disorders
- Others
- Oncology
- End-Use Outlook (Revenue, USD Billion; 2022-2032)
- Hospitals
- Specialty Clinics
- Research & Academic Institutes
- Pharmaceutical & Biotechnology Companies
- Regional Outlook (Revenue, USD Billion; 2022-2032)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Benelux
- Nordic Countries
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Oceania
- ASEAN Countries
- Rest of APAC
- Latin America
- Brazil
- Rest of LATAM
- Middle East & Africa
- GCC Countries
- South Africa
- Israel
- Turkey
- Rest of MEA
- North America